Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study
Main finding · ICU admissionResult — go to the resultHazard ratio 0.79 95% CI 0.69–0.91Authors' conclusion
In patients with type 2 diabetes, SGLT2 inhibitors were independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
Study context
- Population
- Adults with type 2 diabetes newly prescribed SGLT2 or DPP-4 inhibitors, 2015–2019, Hong Kong territory-wide registrypropensity-matched cohort
- Participants
- 27,972 adults
- Exposure
- SGLT2 inhibitors vs DPP-4 inhibitors
- SGLT2 inhibitorsn = 10,308
- DPP-4 inhibitorsn = 17,664reference
- Outcome
- ICU admission
Methodological details1:2 propensity score matched, territory-wide clinical registry, Median follow-up 2.9 years
- 1:2 propensity score matched
- Territory-wide clinical registry
- Median follow-up 2.9 years
Main finding
As reported in the abstract
Hazard ratio
0.79
95% CI 0.69–0.91
P = 0.001
Events by group
SGLT2 inhibitors vs DPP-4 inhibitors
HR 0.79 (95% CI 0.69–0.91); P = 0.001
Observational data: associations, not effects.
Further findings
| Outcome | SGLT2 inhibitors | DPP-4 inhibitors | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause mortality | 3.1% | 7.5% | 0.44 (0.38–0.49) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
ICU admissions for sepsis
P = 0.001
Mortality due to sepsis
P < 0.001
Severity of illness on ICU admission (APACHE IV-predicted risk of death)
- Lower in SGLT2 inhibitor users
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Crit Care Med. Published 7 April 2023. doi:10. 1097/ ccm. 0000000000005869
Composed by AI from the published abstract and checked against it. How Briefs are made →